Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-102052
Filing Date
2025-08-04
Accepted
2025-08-04 16:30:24
Documents
64
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crsp-20250630.htm   iXBRL 10-Q 2401309
2 EX-10.1 crsp-ex10_1.htm EX-10.1 1635166
3 EX-31.1 crsp-ex31_1.htm EX-31.1 12859
4 EX-31.2 crsp-ex31_2.htm EX-31.2 12859
5 EX-32.1 crsp-ex32_1.htm EX-32.1 12142
  Complete submission text file 0000950170-25-102052.txt   11160906

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250630.xsd EX-101.SCH 1005542
67 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250630_htm.xml XML 1986261
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37923 | Film No.: 251180791
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)